Protalix BioTherapeutics
Posted on: July 26, 2018
By: Kim Berlowitz
With: Comments Off on Protalix BioTherapeutics
Exclusive financial advisor to Protalix on its sale of the U.S. commercialization and development rights for PRX-102 to Chiesi Farmaceutici